Original ArticlePatient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy
Section snippets
Patient population
The institutional review board approved this prospective observational study, which was registered at ClinicalTrials.Gov (NCT01627093). Between 2011 and 2019, patients who had a sinus or sinonasal tumor were recruited to participate and informed consent was obtained. All patients underwent a multidisciplinary evaluation by surgical oncology, medical oncology, and radiation oncology. The primary site of disease was evaluated by using computed tomography (CT) and/or magnetic resonance imaging
Results
This prospective observational study included a total of 64 patients with a median follow-up time of 33 months (interquartile range: 10–52 months). Patients were predominantly Caucasian (77%), male (61%) never-smokers (61%), and a median 55 years years old (interquartile range: 15–89). Olfactory neuroblastoma (ONB; 28%), sinonasal undifferentiated carcinoma (SNUC; 22%), squamous cell carcinoma (SCC; 20%), and adenoid cystic carcinoma (ACC; 16%) were the most common histologic subtypes. Thirty
Discussion
This is the first study to prospectively report on PROs and PATs in patients with sinonasal malignancies treated using PBT, which can serve as a baseline for future study comparison and design of randomized controlled trials. Compared to historical XRT outcomes, acute and late PATs favor PBT. PROs suggest clinically significant changes from pre-treatment to the acute and subacute period, largely driven by PBT to the neck, followed by a gradual return to pre-treatment values in the chronic
Acknowledgement
Funding: Supported in part by Cancer Center Support (Core) Grant P30 CA016672 from the National Cancer Institute, National Institutes of Health, United States.
Disclosure/Conflict of interest:
Dr. Rosenthal serves on the scientific advisory board for Merck. Dr. Phan serves on the scientific advisor board for Cyberknife for Accuray, Inc. Dr. Ferrarotto has consulting/advisory role with Ayala Pharmaceuticals; research funding with OncoMed Pharmaceuticals, G1 Therapeutics, AstraZeneca-MedImmune, EMD
References (33)
- et al.
Sinonasal carcinomas: epidemiology, pathology, and management
Neurosurg Clin N Am
(2013) - et al.
Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment
Int J Radiat Oncol Biol Phys
(2007) - et al.
IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival
Int J Radiat Oncol Biol Phys
(2012) - et al.
Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure
Int J Radiat Oncol Biol Phys
(2012) - et al.
Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?
Int J Radiat Oncol Biol Phys
(2007) - et al.
Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis
Lancet Oncol
(2014) - et al.
Use of mobile device technology to continuously collect patient-reported symptoms during radiation therapy for head and neck cancer: a prospective feasibility study
Adv Radiat Oncol
(2016) - et al.
Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice
Int J Radiat Oncol Biol Phys
(2014) - et al.
Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy
Oral Oncol
(2001) - et al.
Competing risks in survival data analysis
Radiother Oncol
(2019)
Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation
Radiother Oncol
Long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma
Int J Radiat Oncol Biol Phys
A multi-institutional experience of proton beam therapy for sinonasal tumors
Adv Radiat Oncol
Outcomes of sinonasal cancer treated with proton therapy
Int J Radiat Oncol Biol Phys
Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study
Oral Oncol
Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data
Head Neck
Cited by (19)
Radiotherapy of rare head and neck tumors
2023, Cancer/RadiotherapieRadiotherapy of sinonasal cancers
2022, Cancer/RadiotherapieCitation Excerpt :In the highly specific case of a planned microscopically incomplete resection (R1), which needs to be discussed during the multidisciplinary meeting, the role of preoperative irradiation for the purpose of reducing the margins is an area currently being developed, in line with the strategies used for other tumours [41]. For non-resectable tumours, exclusive radiotherapy involves IMRT or proton therapy [42,43]. For non-resectable adenoid cystic carcinomas, exclusive radiotherapy is IMRT or proton therapy.
Management of sinonasal cancers: Survey of UK practice and literature overview
2022, European Journal of Surgical OncologyCitation Excerpt :Favourable disease control and survival outcomes in retrospective series resulted in growing interest in the use of proton beam therapy (PBT) for sinonasal malignancy. The dosimetric properties of protons with sharp lateral penumbra and distal fall-off have potential to reduce radiation doses to normal tissues beyond the target volume and to improve dose-volume coverage [10,11]. A UK multi-centre randomized phase III proton trial PROTIS (PROTon beam therapy Vs IMRT in Sinonasal malignancy) is being developed to assess proton beam therapy versus IMRT.
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
2024, International Forum of Allergy and RhinologyFeasibility of PROMIS using computerized adaptive testing during inpatient rehabilitation
2023, Journal of Patient-Reported Outcomes